Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

17.80USD
11:25am EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.80
Open
$17.80
Day's High
$17.85
Day's Low
$17.55
Volume
15,373
Avg. Vol
110,207
52-wk High
$29.00
52-wk Low
$13.20

Chart for

About

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $497.35
Shares Outstanding(Mil.): 27.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln

* PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​ Source text (http://bit.ly/2BqNSiB) Further company coverage:

Dec 01 2017

BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77

* Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018

Nov 08 2017

BRIEF-Paratek Pharmaceuticals to report Q3 results on Nov 8

* Paratek Pharmaceuticals to report third quarter 2017 financial results and provide update on clinical progress on November 8, 2017 Source text for Eikon: Further company coverage:

Oct 24 2017

BRIEF-Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline

* Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline in patients with difficult to treat comorbid conditions

Oct 06 2017

BRIEF-Paratek Pharma antibiotic granted additional qualified infectious disease product designation by FDA​

* Paratek Pharmaceuticals Inc - its antibiotic omadacycline has been granted additional qualified infectious disease product designation by U.S. FDA​ Source text for Eikon: Further company coverage:

Sep 21 2017

BRIEF-Paratek Pharmaceuticals Inc Q2 loss per share $0.66

* Paratek Pharmaceuticals, Inc. Reports second quarter 2017 financial results and provides clinical update

Aug 02 2017

BRIEF-Paratek Pharmaceuticals Q2 loss per share $0.66

* Q2 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S Source text for Eikon: (http://bit.ly/2f7JhMk) Further company coverage:

Aug 02 2017

BRIEF-Paratek says Omadacycline showed high clinical success rates for infections by Absssi pathogens

* Says phase 3 study of oral-only dosing of Omadacycline met all primary, secondary endpoints in acute bacterial skin infections

Jul 17 2017

BRIEF-Paratek Pharma Inc says co and Paratek Pharma LLC entered into amendment No. 3 to loan and security agreement

* Paratek pharmaceuticals inc - on june 27, co and paratek pharma, llc entered into amendment no. 3 to loan and security agreement dated sept. 30, 2015

Jun 29 2017

Earnings vs. Estimates